Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
|Articles|June 24, 2013
- June 2013
- Volume 17
- Issue 1
Activity Helps Hot Flashes & Night Sweats
Advertisement
According to a study published online on March 27, 2013, in Menopause, women who are more active during the day experience less hot flashes or night sweats and also report better sleep. Women 54 to 63 years old wore sleep monitors, kept sleep diaries, and completed questionnaires about daily physical activity. Women with high levels of activity had fewer awakenings and reported better sleep.
Articles in this issue
over 13 years ago
Pain Control: Using Nonprescription Analgesicsover 13 years ago
US-Born Children Have More Asthma, Allergies Than Immigrant Peersover 13 years ago
Finding Effective Relief for Constipationover 13 years ago
Multiple Factors Linked to Readmission After GI Surgeryover 13 years ago
Case Studies in Self-Careover 13 years ago
Multivitamin/Multimineral Supplement Useover 13 years ago
Acetaminophen Helps Death Fearsover 13 years ago
2012-2013 The Medical Year in Reviewover 13 years ago
Pharmacy Times: Leading the Wayover 13 years ago
Weight Gain During Pregnancy Increases Laceration RiskAdvertisement
Related to this article
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Two Gene Therapy Approvals Expand Options for Rare Immune Disorders as Access Challenges Persist
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
RSV Hospitalization Linked to Higher Short-Term Risk of Invasive Pneumococcal Disease
5